Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Nxera Pharma Reports Progress On Partnered Schizophrenia Candidate NBI-1117568
Details : Under the license, Neurocrine gains development and commercialization rights to a portfolio of novel clinical and preclinical muscarinic M4 receptor agonists, NBI-1117568 for treating schizophrenia.
Product Name : NBI-1117568
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
April 16, 2024
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Nxera to Receive $35M from Neurocrine upon Positive Ph 2 Data for NBI-1117568
Details : Under the licensing agreement, Neurocrine gains development and commercialization rights to a broad portfolio of muscarinic M4 receptor agonists, NBI-1117568 for the treatment of Schizophrenia.
Product Name : NBI-1117568
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
January 09, 2024
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The observed safety and tolerability profile for patients with borderline personality disorder was consistent with the safety and tolerability profile observed for patients treated with brexpiprazole in other indications.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Luvadaxistat
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,015.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.
Product Name : TAK-831
Product Type : Other Small Molecule
Upfront Cash : $120.0 million
June 16, 2020
Lead Product(s) : Luvadaxistat
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,015.0 million
Deal Type : Collaboration